Cargando…
Should Cefazolin Be the First-line Antimicrobial Prophylaxis Choice in Patients Undergoing Hysterectomy? A Systematic Review and Meta-analysis
BACKGROUND: Current practice guidelines non-preferentially recommend cefazolin, cefoxitin, cefotetan, or ampicillin-sulbactam as first line choices for antibiotic prophylaxis in hysterectomy. We undertook a systematic review to determine whether cefazolin, with no anti-anaerobic activity, is as effe...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631282/ http://dx.doi.org/10.1093/ofid/ofx163.1732 |
_version_ | 1783269429608448000 |
---|---|
author | Pop-Vicas, Aurora Johnson, Stephen Safdar, Nasia |
author_facet | Pop-Vicas, Aurora Johnson, Stephen Safdar, Nasia |
author_sort | Pop-Vicas, Aurora |
collection | PubMed |
description | BACKGROUND: Current practice guidelines non-preferentially recommend cefazolin, cefoxitin, cefotetan, or ampicillin-sulbactam as first line choices for antibiotic prophylaxis in hysterectomy. We undertook a systematic review to determine whether cefazolin, with no anti-anaerobic activity, is as effective as β-lactam antibiotics with anti-anaerobic activity at preventing surgical site-infection (SSI) after abdominal or vaginal hysterectomy. METHODS: We searched PubMed, Scopus, Web of Science, Cochrane Central, and conference proceedings for randomized controlled trials (RCT) in any language up to May 16, 2016. Main search terms included cephalosporins, antibiotic prophylaxis, hysterectomy, surgical wound infection, clinical trials, and random allocation. We included only RCT that measured SSI – our primary outcome – defined as superficial, deep, or organ space. We excluded trials of β-lactams no longer in clinical use. We used predefined data extraction templates, including bias assessment indicators, and performed meta-analyses with random-effects models. RESULTS: Fourteen RCTs met inclusion criteria. There were 98 (5%) SSI among 1,903 patients in the cefazolin group, and 78 (4%) SSI among 1,772 patients in the comparator β-lactam (cefoxitin, cefotetan, cefotaxime, ceftriaxone, ampicillin, amoxicillin/clavulanate, or penicillin) group. The summary estimate showed no significant benefit for cefazolin vs. other β-lactam in reducing SSI (Risk Ratio 1.19; 95% CI 0.88 – 1.62, P = 0.23). Cefazolin had a higher SSI risk when compared with cefoxitin or cefotetan (Risk Ratio 1.67; 95% CI 1.03–2.72, P = 0.04), and a trend for higher SSI risk when compared with cefoxitin, cefotetan, or amoxicillin/clavulanate (Risk Ratio 1.56; 95% CI 0.99–2.49, P = 0.06). Most studies were limited to hysterectomies for benign indications, had variability in prophylaxis duration (single vs. multiple doses) and had unclear or high risk of bias. CONCLUSION: Β-lactam antibiotics with good anti-anaerobic spectrum may be preferable to cefazolin for SSI prevention post-abdominal or vaginal hysterectomy. Antimicrobial prophylaxis for hysterectomy in the setting of advanced malignancy deserves further study. DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-5631282 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-56312822017-11-07 Should Cefazolin Be the First-line Antimicrobial Prophylaxis Choice in Patients Undergoing Hysterectomy? A Systematic Review and Meta-analysis Pop-Vicas, Aurora Johnson, Stephen Safdar, Nasia Open Forum Infect Dis Abstracts BACKGROUND: Current practice guidelines non-preferentially recommend cefazolin, cefoxitin, cefotetan, or ampicillin-sulbactam as first line choices for antibiotic prophylaxis in hysterectomy. We undertook a systematic review to determine whether cefazolin, with no anti-anaerobic activity, is as effective as β-lactam antibiotics with anti-anaerobic activity at preventing surgical site-infection (SSI) after abdominal or vaginal hysterectomy. METHODS: We searched PubMed, Scopus, Web of Science, Cochrane Central, and conference proceedings for randomized controlled trials (RCT) in any language up to May 16, 2016. Main search terms included cephalosporins, antibiotic prophylaxis, hysterectomy, surgical wound infection, clinical trials, and random allocation. We included only RCT that measured SSI – our primary outcome – defined as superficial, deep, or organ space. We excluded trials of β-lactams no longer in clinical use. We used predefined data extraction templates, including bias assessment indicators, and performed meta-analyses with random-effects models. RESULTS: Fourteen RCTs met inclusion criteria. There were 98 (5%) SSI among 1,903 patients in the cefazolin group, and 78 (4%) SSI among 1,772 patients in the comparator β-lactam (cefoxitin, cefotetan, cefotaxime, ceftriaxone, ampicillin, amoxicillin/clavulanate, or penicillin) group. The summary estimate showed no significant benefit for cefazolin vs. other β-lactam in reducing SSI (Risk Ratio 1.19; 95% CI 0.88 – 1.62, P = 0.23). Cefazolin had a higher SSI risk when compared with cefoxitin or cefotetan (Risk Ratio 1.67; 95% CI 1.03–2.72, P = 0.04), and a trend for higher SSI risk when compared with cefoxitin, cefotetan, or amoxicillin/clavulanate (Risk Ratio 1.56; 95% CI 0.99–2.49, P = 0.06). Most studies were limited to hysterectomies for benign indications, had variability in prophylaxis duration (single vs. multiple doses) and had unclear or high risk of bias. CONCLUSION: Β-lactam antibiotics with good anti-anaerobic spectrum may be preferable to cefazolin for SSI prevention post-abdominal or vaginal hysterectomy. Antimicrobial prophylaxis for hysterectomy in the setting of advanced malignancy deserves further study. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2017-10-04 /pmc/articles/PMC5631282/ http://dx.doi.org/10.1093/ofid/ofx163.1732 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Pop-Vicas, Aurora Johnson, Stephen Safdar, Nasia Should Cefazolin Be the First-line Antimicrobial Prophylaxis Choice in Patients Undergoing Hysterectomy? A Systematic Review and Meta-analysis |
title | Should Cefazolin Be the First-line Antimicrobial Prophylaxis Choice in Patients Undergoing Hysterectomy? A Systematic Review and Meta-analysis |
title_full | Should Cefazolin Be the First-line Antimicrobial Prophylaxis Choice in Patients Undergoing Hysterectomy? A Systematic Review and Meta-analysis |
title_fullStr | Should Cefazolin Be the First-line Antimicrobial Prophylaxis Choice in Patients Undergoing Hysterectomy? A Systematic Review and Meta-analysis |
title_full_unstemmed | Should Cefazolin Be the First-line Antimicrobial Prophylaxis Choice in Patients Undergoing Hysterectomy? A Systematic Review and Meta-analysis |
title_short | Should Cefazolin Be the First-line Antimicrobial Prophylaxis Choice in Patients Undergoing Hysterectomy? A Systematic Review and Meta-analysis |
title_sort | should cefazolin be the first-line antimicrobial prophylaxis choice in patients undergoing hysterectomy? a systematic review and meta-analysis |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631282/ http://dx.doi.org/10.1093/ofid/ofx163.1732 |
work_keys_str_mv | AT popvicasaurora shouldcefazolinbethefirstlineantimicrobialprophylaxischoiceinpatientsundergoinghysterectomyasystematicreviewandmetaanalysis AT johnsonstephen shouldcefazolinbethefirstlineantimicrobialprophylaxischoiceinpatientsundergoinghysterectomyasystematicreviewandmetaanalysis AT safdarnasia shouldcefazolinbethefirstlineantimicrobialprophylaxischoiceinpatientsundergoinghysterectomyasystematicreviewandmetaanalysis |